Find policies, billing codes, payers, states, and providers
Coblation Clinical Policy Bulletin
Customize your policy alerts
Sign up for Aetna Policy 0475 alerts
Get alerted when Policy 0475 changes without checking for updates manually.
Monitor payer policy activity
Aetna Clinical Policy Bulletin defining medical necessity and investigational/experimental determinations for Coblation procedures across multiple anatomic sites and indications, plus lists of applicable CPT/HCPCS/ICD-10 codes and background/evidence summary. This is part 1 of 4; contains medical necessity statement, experimental/investigational list, related policies, codes for covered and not-covered indications, and extensive background/evidence discussion.
No material clinical or coverage changes in this update.
Coverage Summary
Scope: Aetna Clinical Policy Bulletin (0475) defines medical necessity and investigational determinations for Coblation procedures across multiple anatomic sites and indications, with lists of applicable CPT/HCPCS/ICD-10 codes and a summary of background evidence (part 1 of 4).
Stance overview: Coverage is mixed — Coblation tonsillectomy is defined as medical necessary for specific indications, while numerous other Coblation applications are considered experimental and investigational; the document’s primary clinical focus and strongest evidence base relate to tonsillectomy, with many other uses remaining preliminary or insufficiently supported.
Medical-Necessity Criteria
Medical Necessity
Aetna considers Coblation tonsillectomy medical necessary for the treatment of any of the following:
Medical Necessity - indications
- Peri-tonsillar abscess.
- Recurrent middle ear infection where tonsillar hypertrophy is believed to be an exacerbating factor.
- Recurrent or chronic tonsillar infection.
- Tonsillar hypertrophy leading to respiratory symptoms or airway obstruction.
Experimental, Investigational, and Not Medically Necessary
Experimental and Investigational (Not Medically Necessary)
Aetna considers the following interventions experimental and investigational because the effectiveness has not been established:
Experimental and Investigational interventions
- Cervical Coblation nucleoplasty for the treatment of cervicogenic headache
- Coblation adenoidectomy
- Coblation annuloplasty for the treatment of cervical discogenic pain
- Coblation-assisted arytenoidectomy for the treatment of infants with vocal cord paralysis
- Coblation-assisted management of airway stenosis
- Coblation-assisted surgical resection for the treatment of rhinosporidiosis
- Coblation-assisted turbinoplasty and nasal Coblation plasma surgery for the treatment of allergic rhinitis
- Coblation devices (e.g., Topaz Microdebrider) for the treatment of musculoskeletal conditions including insertional Achilles tendinopathy, and lateral epicondylitis
- Coblation for soft tissue stenosis of the external auditory canal
- Coblation nasal septal swell body reduction for the treatment of nasal obstruction
- Coblation non-thermal volumetric tissue reduction for: Dysphagia; Laryngo-tracheal papillomatosis; Nasopharyngeal angiofibroma; Removing soft tissue during arthroscopic surgery; Spinal osteoid osteomas; Wound debridement
- Coblation of femoral and sciatic nerve for the treatment of stump pain and phantom limb pain
- Computed tomography (CT)-guided percutaneous Coblation of the thoracic nerve root for the treatment of post-herpetic neuralgia
- Cordotomy by Coblation for the treatment of vocal fold immobility
- CT-guided Gasserian ganglion nerve Coblation for the treatment of trigeminal neuralgia
- Endoscopic Coblation cauterization for the treatment of pyriform sinus fistula
- Percutaneous disc decompression with Coblation nucleoplasty for the treatment of cervical vertigo
- Percutaneous thoracic paravertebral nerve Coblation for the treatment of thoracic neuropathic pain
- Radiofrequency (RF) Coblation for the treatment of congenital nasopharyngeal teratoma
- RF Coblation-assisted transoral surgery for the treatment of oropharyngeal squamous cell carcinoma, and supraglottic laryngeal carcinoma
- RF Coblation for the treatment of glottis cancer
- RF Coblation for the treatment of laryngeal cancer
- RF Coblation for the treatment of osteochondritis dissecans lesions
- RF Coblation for the treatment of peri-scapular tendinopathy
- RF Coblation for the treatment of tracheal tumors
- RF Coblation, with and without gastrocnemius release, for the treatment of plantar fasciitis
- RF to the nasal valve (Vivaer Nasal Airway Remodeling (Aerin Medical)) for the treatment of nasal airway obstruction
- Transoral RF Coblation for the treatment of laryngopharyngeal vascular lesions
- Videolaryngoscope-assisted Coblation for the treatment of epiglottic cysts
Coverage stance: The policy’s overall stance is mixed, explicitly designating Coblation tonsillectomy as medically necessary for a defined set of indications, and listing numerous other Coblation interventions as experimental and investigational because effectiveness has not been established.
Coding note: Many CPT, HCPCS, and ICD-10 codes are specifically listed as not covered for investigational indications in the policy; detailed coding information and examples are provided in the Coding section of the bulletin.
Clinical Evidence Summaries
Clinical Evidence Summaries (narrative; no explicit coverage criteria in this part)
This section summarizes clinical studies and level of evidence for various coblation applications:
Clinical Evidence Summaries
- Temperature-controlled radiofrequency (TCRF) / Vivaer Nasal Airway Remodeling System for internal nasal valve collapse: multiple single-arm prospective studies, RCT (single-blinded sham-controlled), and long-term follow-up reporting improvement in NOSE scores through 3–48 months; RCT showed superiority to sham at 3 months.
- Coblation-assisted arytenoidectomy (CSA / ECPA) for infants with bilateral vocal cord paralysis: small case series and retrospective reviews reporting extubation success and surgical success rates (e.g., Hu et al 2019: 14 patients, 13 extubated; Tan et al 2022: 33 infants, 87.9% surgical success).
- RF Coblation for tracheal tumors: case-series (3 cases) showing feasibility; authors call for larger studies.
- Coblation devices (Topaz microdebrider) for insertional Achilles tendinopathy and lateral epicondylitis: systematic review and small studies suggesting favorable outcomes vs other surgical techniques but heterogeneous methods and small sample sizes; further RCTs planned/needed.
- RFC-assisted transoral surgery (RFC-TOS) for supraglottic laryngeal carcinoma and oropharyngeal squamous cell carcinoma: retrospective comparative studies showing shorter operative time, less blood loss, faster recovery, lower costs vs open surgery with similar oncologic outcomes; authors recommend further trials.
- RFC with/without gastrocnemius release for plantar fasciitis: retrospective analyses — evidence incomplete in this excerpt.
Background summary: Coblation is a low-temperature, plasma-mediated radiofrequency tissue-dissociation method intended to remove tissue with less thermal damage than traditional electrosurgery or lasers, using an electrically conductive fluid to generate a plasma layer that dissociates tissue molecules.
Evidence limitations: While the document cites supportive evidence for Coblation tonsillectomy (including randomized and large cohort studies and NICE guidance), it states that evidence is insufficient or preliminary for many other applications (musculoskeletal uses, nucleoplasty, various ENT and pain indications). The strongest evidence outside tonsillectomy is for temperature-controlled radiofrequency/Vivaer for internal nasal valve collapse, but many other uses are based on small case series or nonrandomized studies and require further validation.
Coding
| 30465 | Repair of nasal vestibular stenosis (eg, spreader grafting, lateral nasal wall reconstruction) [not covered for Vivaer Nasal Airway Remodeling] |
| 30469 | Repair of nasal valve collapse with low energy, temperature-controlled (ie, radiofrequency) subcutaneous/submucosal remodeling. |
| 29800-29999 | Endoscopy/arthroscopy (other CPT codes related to CPB) |
| 31254-31288 | Nasal/sinus endoscopy, surgical; ethmoid, maxillary, frontal, or sphenoid. |
| 31400 | Arytenoidectomy or arytenoidopexy, external approach. |
| 31560 | Laryngoscopy, direct, operative, with arytenoidectomy. |
| 31561 | Laryngoscopy, direct, operative, with arytenoidectomy; with operating microscope or telescope. |
| 42820-42826 | Tonsillectomy. |
| 30801-30802 | Ablation, soft tissue of inferior turbinates, unilateral or bilateral, any method (eg, electrocautery, radiofrequency ablation, or tissue volume reduction) [listed as CPT codes covered if selection criteria are met] |
| 64633 | Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance; cervical or thoracic, single facet joint (listed as CPT codes not covered for paravertebral nerve Coblation). |
| No specific code | Coblation devices (e.g., Topaz Microdebrider) - no specific HCPCS code listed. |
| J03.00-J03.91 | Acute tonsillitis. |
| J35.01 | Chronic tonsillitis. |
| J35.1 | Hypertrophy of tonsils. |
| J36 | Peritonsillar abscess. |
| B02.22 | Postherpetic trigeminal neuralgia. |
| B48.1 | Rhinosporidiosis. |
| C10.0-C10.9 | Malignant neoplasm of oropharynx. |
| C32.0-C32.9 | Malignant neoplasm of larynx. |
| C33 | Malignant neoplasm of trachea. |
| D10.6 | Benign neoplasm of nasopharynx. |
| D14.1 | Benign neoplasm of larynx [papillomatosis of larynx]. |
| D14.2 | Benign neoplasm of trachea [papillomatosis of trachea]. |
| D16.6 | Benign neoplasm of vertebral column [spinal osteoid osteomas]. |
| D37.05 | Neoplasm of uncertain behavior of pharynx [congenital nasopharyngeal teratoma]. |
| No codes listed |
Provider Actions
Document indication for tonsillectomy
Document the specific indication for Coblation tonsillectomy in the medical record and operative note.
- Applicable CPT codes: 42820-42826
- Applicable ICD-10 codes (when selection criteria met): J03.00–J03.91 (acute tonsillitis); J35.01 (chronic tonsillitis); J35.1 (hypertrophy of tonsils); J36 (peritonsillar abscess)
Avoid billing Coblation for investigational indications
Do not bill Coblation procedures for indications listed as experimental/investigational in the policy. Claims submitted with diagnosis codes corresponding to these not-covered indications may be denied.
- Example ICD-10 codes from the not-covered list: B02.22 (postherpetic trigeminal neuralgia); G50.0 (trigeminal neuralgia); D16.6 (benign neoplasm of vertebral column); J34.3 (hypertrophy of nasal turbinates); J34.89 (other specified disorders of nose and nasal sinuses); J39.8 (other specified diseases of upper respiratory tract [airway stenosis]); M00.00–M99.9 (diseases of the musculoskeletal system and connective tissue); and others listed in the policy
Use of validated outcome measures in evidence
Document baseline and postoperative NOSE Scale scores when evaluating Coblation (temperature-controlled RF) treatment effectiveness for nasal valve/nasal airway obstruction, as studies used the NOSE Scale as primary patient-reported outcome.
- >= 20% reduction in NOSE Scale score or >= 1 reduction in NOSE clinical severity category (primary responder threshold used in many studies)
- Alternative responder threshold: >= 15-point improvement on NOSE score (used in some studies)
Patient selection details referenced in studies
When selecting patients for nasal valve RF treatment, document details that match study eligibility and selection used in the evidence base.
- Document that internal nasal valve (nasal valve collapse) is the primary or significant contributor to nasal airway obstruction
- Document baseline NOSE Scale score (trials enrolled patients with baseline NOSE >=55–60 when applicable)
- Document prior response to temporary nasal valve dilation or lateralization maneuvers if performed (many studies required a positive response)
Definitions
Definitions:
• Coblation: A non-thermal volumetric tissue removal method using a low-temperature plasma generated in conductive fluid that dissociates tissue molecules (plasma-mediated radiofrequency ablation).
• Vivaer: A low-energy bipolar radiofrequency device/system for intranasal remodeling of the internal nasal valve (temperature-controlled RF).
• NOSE Scale: Nasal Obstruction Symptom Evaluation, a validated patient-reported outcome measure for nasal obstruction used as the primary endpoint in many nasal valve studies.
• TCRF / Vivaer: Temperature-controlled radiofrequency device/system used for in-office internal nasal valve remodeling (same technology family as Vivaer).
• Device technology description: Plasma-mediated bipolar radiofrequency tissue ablation/dissolution technology with a low thermal profile (designed to limit temperatures typically <50–60°C) used for tissue removal/ablation with intent to reduce collateral thermal injury.
Evidence Highlights
| Study (year/author) | Design / n | Key finding |
|---|---|---|
| Silvers et al (2021) | Prospective multicenter randomized, single-blinded RCT; active n=77 vs sham n=41 | Responder rate at 3 months: Active 88.3% vs Sham 42.5% (p<0.001); greater mean NOSE score reduction in active arm; 3 possibly related AEs resolved. |
| William/Yao (2021) | Prospective, multi-center single-arm study; n=122 | NOSE score improved from ~80.3 to 32.9 at 3 months (p<0.001); 91.6% had ≥20% improvement or ≥1 severity category improvement. |
| Jacobowitz et al (2019, 48-month follow-up) | Prospective non-randomized multicenter case-series; initial n=50, extended follow-up n=29 | Sustained NOSE improvements through 48 months; baseline 81.0 to 25.7 at 48 months; responder rates ≥92.9% at multiple timepoints (≥15-point improvement threshold). |
| Han et al (2022) | Prospective randomized single-blinded multicenter trial with crossover; combined active n=108 (77 index + 31 crossover) | At 12 months combined active-treatment responder rate 89.8%; mean NOSE improvement sustained; no device/procedure-related serious AEs reported. |
| Jacobowitz (initial) / Ephrat (2019/2021) | Prospective non-randomized, multi-center case-series; Jacobowitz n=50; Ephrat extended single-arm cohorts (n up to 49/39) | Mean NOSE decreased from ~79.9 to 24.7 at 26 weeks; high patient satisfaction; studies uncontrolled but show marked short-term benefit. |
| Luo et al (2020) | Retrospective case series; n=77 (CT-guided percutaneous thoracic nerve root Coblation for PHN) | VAS decreased from 7.22 to ~3.0 at follow-ups; responder rates ~75%-78% across timepoints; mostly mild numbness; no severe AEs reported. |
| Cochrane review (Burton & Doree, 2007) | Systematic review | Inadequate evidence to determine superiority of coblation tonsillectomy for post-op pain/recovery; audit data suggested possible higher postoperative bleeding; need for large well-designed RCTs and audits. |
| Belloso et al (2003) | Comparative large cohort study; Coblation n=844 vs traditional n=743 | Coblation tonsillectomy associated with less delayed hemorrhage and less post-op pain; fewer secondary infections and lower secondary hemorrhage rates reported. |
| Arya et al (2003) / Timms & Temple (2002) | Double-blind randomized studies (small): Arya n=14; Timms study noted | Arya RCT: no significant difference in post-op pain between coblation tonsillotomy and coblation tonsillectomy (small n); Timms double-blind RCTs exist supporting evaluation but sample sizes limited. |
| Guan et al (2022) | Retrospective comparative study; supraglottic carcinoma RFC-TOS n=23 vs open n=23 | RFC-TOS had lower operative time, blood loss, faster recovery, lower costs and similar 5-year oncologic outcomes versus open surgery. |
| Tan et al (2022) | Retrospective review; infants with idiopathic BVCP n=33 undergoing endoscopic Coblation-assisted partial arytenoidectomy (ECPA) | Surgical success 87.9% overall; 95.6% success for BVCP alone vs 70.0% when combined with other airway abnormalities. |
| Benninger et al (2018, 2022) | Retrospective case-series/cohort; 2018 n=19; 2022 multicenter review n=94 | Coblation cordotomy for BVFI showed improvements in breathing/stridor and VHI; 2022 series enabled de-cannulation in 21/25 tracheotomy patients; revision rate ~22%. |
| Tasto et al (2005) / Velez et al (2022) | Small prospective case series and systematic review for microtenotomy/Coblation in tendinopathy (e.g., lateral epicondylitis) | Studies suggest favorable pain and functional outcomes versus other techniques but evidence is heterogeneous and limited; larger RCTs needed. |
| Silvers / Yao / William (pooled nasal valve evidence) | Multiple RCTs and single-arm studies (see above) with varied sample sizes | Overall evidence for temperature-controlled RF (Vivaer/TCRF) shows consistent NOSE score improvements and superiority to sham in RCT at 3 months; sustained benefits reported up to 48 months in single-arm follow-ups. |
Revision History
Policy effective date. Policy number 0475. Status: CURRENT.
Policy last reviewed. Policy number 0475. Status: CURRENT.
Next scheduled policy review date. Policy number 0475. Status: CURRENT.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.